April, 2019
MPNRF Under the Microscope
Clinical Trial for Avid 200 Doses First MF Patient
A TGF-Beta inhibitor – AVID 200 – is joining the race for new therapies for myeloproliferative neoplasms. In a press release published today, Forbius Biologics Inc. announced that the first myelofibrosis patient has been dosed in their phase 1b myelofibrosis trial of AVID 200, a novel TGF-Beta inhibitor. The investigator-initiated trial is being run by the MPN Research Consortium, a global collective of MPN researchers working to accelerate the study of MPNs and drug trials, headed by Dr. Ronald Hoffman at Mt Sinai School of Medicine. The hope for this class of drugs and AVID 200, in particular, is that it will have a positive impact on both bone marrow fibrosis and anemia as well as relieve symptoms.

“The MPN-RC is funded by the NIH to conduct clinical trials based on the most promising pre-clinical MPN research. The goal of the consortium is to adapt quickly in response to scientific advances and a changing clinical landscape, in order to develop effective therapeutics for MPN patients.”

MPNRF supported the inception of the MPD-RC in 2006 and is encouraged by their continued work and investment in MPNs. To learn more about this clinical trial visi clinicaltrials.gov  and speak to your hematologist.
Mother's Day is approaching fast, do you have your gift for the special woman in your life?

Do your shopping at smile.amazon.com and select MPNRF as your charity of choice! A percentage of what you spend will be donated to The MPN Research Foundation.
Upcoming Patient Events
MPN Advocacy & Education International is holding two, back to back MPN patient and caregiver events in New York, NY.
2nd Annual Pediatric & Young
Adult MPN Patient Program

May 16, 2019
Park Hyatt New York
153 West 57th Street
New York, NY
MPN Patient and
Caregiver Program

May 17, 2019
Park Hyatt New York
153 West 57th Street
New York, NY
Participate in Research
The MPN Genome Advocacy Project
Are you interested in participating in MPN research from the comfort of your home? Look no further than the anonymous survey below. Created by The MPN Genome Study Group, the project, The MPN Genome Advocacy Project (M-GAP), was created to help raise awareness and demand for MPN mutational testing and to generate a broader understanding of the mutations relating to MPNs. With routine genetic testing, MPN patients will be able to make better diagnostic, prognostic, and treatment-related decisions.
Drug : KRT-232
Company : Kartos Therapeutics, Inc.

Study name : An Open-Label, Phase 2a/2b Study of KRT-232 in in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor

Enrolling : Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed a JAK Inhibitor

To learn more click  here .
Drug : IMG-7289
Company:  Imago BioSciences, Inc.

Study name : A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis

Enrolling : Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, Primary MF, Post PV-MF & Post ET-MF

To learn more click  here .
Upcoming May Events
There are several patient and caregiver events coming up in the month of May! Head over to our MPN Community Calendar on MPNRF's website and check out the many educational meetings and webinars taking place!